Articles tagged with Cancer Medication
Researchers found that adding MS drug teriflunomide to targeted cancer therapy significantly shrinks glioblastoma tumors and improves mouse survival. The treatment targets cancer stem cells, which are responsible for tumor recurrence.
Researchers at Columbia University Irving Medical Center have identified a potential new therapy for pancreatic cancer. Their experimental compound, PTC596, has shown to be effective in combination with standard treatment, extending survival by three times in genetically engineered mice.
Researchers have identified a combination of gene mutations that are frequently found together in endometrial cancer and endometriosis-associated ovarian cancer. The ARID1A and PIK3CA genes' mutations can lead to uncontrolled cell growth, increasing the risk of cancer.
Researchers have identified a potential combination targeted therapy for a deadly type of leukemia found in some infants, which was linked to high levels of the BCL6 protein and poor outcomes. The therapy involves 'turning off' the BCL6 protein using ABT-199, promising a lifesaving treatment option for babies and young children.
Independent charity prescription drug assistance programs in the US primarily cover insured patients, leaving out those without health insurance. These programs tend to favor higher-priced brand-name drugs over generics.
Researchers used artificial intelligence to identify five new types of breast cancer with distinct patterns of response to treatment, including two that are more likely to benefit from immunotherapy. The study aims to personalize treatment for women with breast cancer by selecting patients for different drugs in clinical trials.
Biomedical researchers have created three-dimensional cell structures from diseased tissue of patients to study endometrial diseases like endometriosis and cancer. This new biobank can help unravel disorders and test drugs for effective treatments.
Researchers at Stanford University School of Medicine have discovered a new 'don't eat me' signal used by cancer cells to evade immune detection. Blocking this signal allows immune cells to attack and destroy cancer cells in mice implanted with human cancers, providing a potential basis for new anti-cancer therapies.
A phase-3 trial shows that combining rituximab with ibrutinib keeps patients disease-free for nearly three years and improves overall survival rates. The new treatment is more effective and better tolerated than traditional chemotherapy, revolutionizing the standard of care for chronic lymphocytic leukemia.
Researchers at the University of Birmingham have successfully extracted and modified a compound from feverfew to kill chronic lymphocytic leukemia cells in laboratory experiments. The compound, parthenolide, works by increasing reactive oxygen species levels in cancer cells, causing them to die.
The National Cancer Institute has recognized Sylvester Comprehensive Cancer Center as a top-tier US cancer center due to its outstanding research and clinical care. The designation is a testament to the dedication of every member of the cancer center.
Researchers analyzed 10,225 patient samples from 32 different cancers to better understand TP53 mutations. They found that TP53 mutations were more frequent in patients with poorer survival rates but also identified a way to predict prognosis based on four upregulated genes.
Researchers at Tokyo University of Agriculture and Technology have developed a novel experimental model for dog bladder cancer using 3D organoid culture from urine samples. The model allows for quick determination of chemotherapy and identification of new biomarkers for both human and canine bladder cancer.
Researchers at UVA have identified Hullk, a non-coding RNA that regulates biological processes in cells. The discovery offers potential for targeting and stopping prostate cancer progression with fewer side effects.
A breakthrough new drug CBL0137 has proven effective in mice treated with chemotherapy and is being tested as a potential treatment for all types of cancer, including solid tumours. The drug works by reactivating the body's P53 pathway to kill off damaged cells.
Australian researchers have identified a gene called JMJD6 that plays a key role in the most aggressive form of neuroblastoma. The discovery opens up new possibilities for targeted drug therapy, with promising results shown in animal models.
The freely available data set includes unique comparisons of almost 1,000 cancer cell lines' responses to 453 licensed and experimental drugs. The dataset offers a rich resource for cancer scientists to discover more about how cancer cells work and generate new therapeutics and drug combinations.
A study published in JAMA Oncology reports higher than expected five-year survival rates for patients with melanoma, renal cell carcinoma, and non-small-cell lung cancer treated with nivolumab. The treatment showed durable responses and improved outcomes for patients without cancer-related symptoms.
A new, non-invasive bladder cancer treatment method uses a 'liquid biopsy' from urine to identify molecular underpinnings of each patient's unique bladder cancer. The technique, called conditional reprogramming or CR, has shown promising results in detecting and treating the disease.
A combination of two FDA-approved drugs significantly extended the lives of mice injected with human ovarian cancer cells, altering the natural ratio of macrophages and improving survival. The treatment targets M1 macrophages, which can protect against tumor growth and progression.
A new study published in Science Advances reveals that a cellular switch called CREB plays a key role in directing tumor growth in non-small-cell lung cancer. Researchers found that blocking this switch could have therapeutic benefits for patients with this deadly type of cancer.
Researchers at UT Southwestern Medical Center discovered a new molecular mechanism that indicates PARP inhibitors could be effective in treating all cancers where the drugs are used, including ovarian and prostate cancers. A potential biomarker has been identified, which may indicate when patients can benefit from these drugs.
The FDA has approved erdafitinib as a targeted therapy for patients with advanced bladder cancer who have specific gene mutations in the FGFR3 gene. The drug achieved a 40% overall response rate and was well-tolerated, offering an alternative to existing treatments.
A study by University of Notre Dame researcher Siyuan Zhang and collaborators identified a gene that makes triple-negative breast cancer (TNBC) cells vulnerable to existing therapies. The discovery suggests that a targeted drug therapy may be effective for this aggressive type of breast cancer.
Researchers at Vanderbilt University Medical Center investigated a cancer patient's fatal encephalitis after immunotherapy treatment, revealing a rare viral infection trigger. The study found that a specific T cell population may play a major role in immune-related adverse events and anti-tumor responses.
A new study using a cryo-electron microscope provides critical information for developing anti-nausea drugs that are effective against cancer patients' vomiting side effects. The high-resolution images reveal the attachment site of widely-used setron drugs on serotonin receptors, offering insights into how their design might be improved.
A gene test can identify prostate cancer patients who are likely to respond to a new type of treatment that uses radioactive particles to kill cancer cells. The test detects genetic weaknesses in DNA repair genes, which is linked to high levels of PSMA on the surface of cancer cells.
A new mathematical model describes how highly concentrated antibody solutions separate into different phases, similar to an oil and water mixture. This separation can reduce the stability and shelf-life of some drugs that use monoclonal antibodies.
A Northwestern University study found that many deadliest cancers, such as colon, lung, and liver cancer, receive significantly less nonprofit research funding than breast cancer, leukemia, and other well-funded types. This underfunding could impact research, drug development, and FDA approvals for these life-altering diseases.
Researchers at the University of Minnesota Medical School have identified a cellular mechanism that contributes to drug resistance in colon cancer. The study found that KRAS proteins can transfer between cancer cells via long, thin extensions called tunneling nanotubes, leading to more aggressive and invasive cancer behavior.
Researchers have discovered the precise mechanism behind 5-Fluorouracil resistance in cancer, revealing a previously unknown protein called BOK as the key to understanding this phenomenon. Without BOK, cancer cells become dormant and can survive chemotherapy treatment before mutating into more aggressive forms.
A new study reveals a significantly higher prevalence of anal cancer precursors in women living with HIV compared to previous reports. The researchers recommend developing cost-effective detection and management strategies for this population.
The University of Colorado Cancer Center is enrolling patients in a Phase II clinical trial evaluating the effectiveness of Rucaparib, a PARP inhibitor, as maintenance therapy for endometrial cancer. The trial aims to determine the drug's ability to prevent cancer cell growth and death in patients with metastatic or recurrent disease.
Researchers found adding pembrolizumab to definitive treatment increased overall average PFS by 19.1 months, compared to 6.6 months in historical averages. The study showed the treatment did not lead to new safety issues or decreased patient quality of life.
A new study found that combining targeted drugs palbociclib and crizotinib is significantly more effective against cancer cells in the laboratory than either drug used alone. The combination approach may broaden the clinical use of palbociclib beyond breast cancer to include other tumour types.
A new study from the University of Pittsburgh found a correlation between pre-pregnancy body-mass index (BMI) in mothers and subsequent cancer diagnosis in their offspring. Children born to severely obese mothers had a 57% higher risk of developing leukemia before age 5.
A study published in Journal of Drugs in Dermatology highlights the need for tailored skin cancer prevention programs to reach non-white and younger populations. The research found significant gaps in sun protective knowledge and behavior among these groups, emphasizing the importance of comprehensive community-based solutions.
Researchers propose a 'first-strike' and 'second-strike' strategy to tackle metastatic cancer. The approach aims to eliminate the entire cancer population by sequencing drugs, rather than relying on maximum tolerated dose therapy. This could lead to better outcomes for patients with widespread disease.
Scientists at the University of Toledo have discovered a new class of cancer-killing agents that target and destroy cancer stem cells. These findings hold promise for developing effective treatments for sarcomas and a subtype of breast cancer known as claudin-low breast cancer.
Researchers at Purdue University have discovered a novel set of MYC promoter G-quadruplex stabilizers that demonstrate anticancer activity in human cancer cell cultures. The agents downregulate the expression of the MYC oncogene, which is overexpressed in cancer and associated with all aspects of cancer development.
A new study from the University of Cambridge found that patients with diabetes who have an empathetic GP are at a lower risk of early death. The study analyzed data from 867 individuals and found that those with better experiences of empathy had a significantly lower risk of death over the subsequent 10 years.
Researchers at Moffitt Cancer Center have identified a new drug combination that is effective against metastatic uveal melanoma cells. The combination of an MEK inhibitor and a histone deacetylase (HDAC) inhibitor, such as panobinostat, has been shown to prevent resistance to the MEK inhibitor and enhance its anti-tumor properties.
Researchers found that immune cells were six times more active in tumours resistant to cetuximab. Immunotherapies designed to boost the immune system could be effective against these cancers. A phase II clinical trial has begun to test this approach.
Researchers have identified how precision cancer drugs work, enabling new applications and combination therapies. The discovery reveals the role of PARP proteins in DNA repair, increasing sensitivity to radiation therapy and potential for treating aggressive cancers.
Researchers discovered that bats have higher levels of ABCB1 protein, which reduces DNA damage and cancer incidence. Blocking ABCB1 in bat cells triggers toxic chemical accumulation, leading to cell death. This finding could lead to future therapies for humans to prevent or treat cancer.
A study of 298,434 patients found that married women had a better prognosis after breast cancer diagnosis compared to single or divorced patients. Single patients showed improved outcomes only among white patients and those aged over 35 with hormone receptor-positive tumors.
Researchers at Tokyo University of Science discover that the anticonvulsant drug papaverine blocks the binding of high-mobility group box 1 (HMGB1) to its receptor, reducing inflammation in sepsis and cancer. The study uses a novel computer-based docking approach to find alternative uses for existing drugs.
Researchers developed a computer model that simulates the metabolism of cancer cells, identifying effective drug combinations and predicting tumor growth inhibition. The model has been tested for colorectal cancer and shows promise for other types of cancer, potentially reducing development time and cost.
Researchers found that Medicare beneficiaries with high annual drug spending may pay more out-of-pocket for generics than brands if they use expensive specialty drugs. The study's lead author argues that policy changes are needed to address the issue and ensure generic drug users aren't overpaying.
Research suggests that PI3K inhibitors, a new class of cancer drugs, may cause an increase in pre-cancerous lesions in the pancreas of mice fed high-fat diets. The findings urge doctors to consider a patient's weight before prescribing these drugs, especially for those with pancreatic cancer who are obese.
Researchers have shown that high doses of cyclophosphamide stimulate an immune system attack on lymphoma cells, resolving long-standing questions about the drug's mode of action. The discovery suggests a novel way to spark an immune system strike on certain cancers, particularly those with aggressive characteristics.
Researchers at the University of Akron have developed 3D tumor models that more accurately replicate human tumors than traditional 2D cultures. These models are being used to test new drugs and understand the drivers of triple-negative breast cancer, a type of cancer with limited treatment options.
Researchers found that cancer cells respond differently to targeted drugs based on tumour type and genetic weaknesses. The study suggests rethinking precision medicine and designing clinical trials with both gene faults and tumour type in mind.
A new clinical trial has successfully treated women with HER2-positive breast cancer who have no other treatment options by combining Herceptin with chemotherapy. The two-in-one treatment extended life for patients with high and low levels of the HER2 protein, offering a promising solution to drug resistance.
A study published in JAMA Oncology found that introducing a default physician order into electronic health records reduced daily imaging for cancer patients with advanced cancer by half. This change also saved an average of two minutes per session, resulting in faster treatment courses.
Scientists have identified a novel pathway allowing subcutaneously administered antibodies to bypass the immune system's traditional route. This breakthrough discovery enables targeted delivery of antibodies to the draining lymph node, potentially revolutionizing treatments for inflammatory diseases and cancers.
Researchers developed an algorithm to identify pediatric oncology patients in EHR data, narrowing down patient cohorts for clinical studies. The tool improved accuracy and efficiency in patient selection, paving the way for more effective research on childhood cancers.
Researchers sequenced canine cancer cell lines to identify human-like genetic changes driving canine cancers. The study found 61 genetic variants that match known drivers of human cancer, and showed sensitivity to human medicines.
Researchers found that children with chromosomal defects were almost 12 times more likely to develop cancer than those without birth defects. Children with non-chromosomal defects had a 2.5 times increased risk of cancer compared to those without birth defects.
A University of Colorado Cancer Center study reveals that combining immunotherapy with histone deacetylase (HDAC) inhibition sensitizes cancers to anti-PD1 therapy. HDAC inhibitors upregulate major histocompatibility complex (MHC) proteins, presenting antigens to T cells and making them effective against cancer cells.